Trichomonas vaginalis in Vaginal Samples from Symptomatic Women in Greece: Assessment of Test Performance and Prevalence Rate, and Comparison with European Prevalence Estimates
Acta Microbiologica Hellenica · 11.07.2025 · 70 (3) · 29
DOI: 10.3390/amh70030029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Microbiologica Hellenica, online erschienen am 11.07.2025. Verfasst von Lazaros Tsoukalas und 9 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Trichomonas vaginalis infection (TVI) is the most common curable sexually transmitted infection (STI). In this study, we aimed to assess the performances of different tests for TVI diagnosis in symptomatic Greek women, evaluating the TVI prevalence rate (PR) in Greece and comparing the latter with TVI-PR estimates from Europe. A laboratory-based cross-sectional analysis and a meta-analysis were conducted. Of 399 symptomatic Greek women, 17 had TVI, corresponding to a TVI-PR of 4.3%. The commercial nucleic acid amplification test (NAAT) achieved a sensitivity of 94.1%, which was 6% higher than the sensitivity of the culture method, 35% higher than that of the wet mount test, and 59% higher than that of the Giemsa stain test. The wet mount test achieved the lowest positive predictive value of 76.9%. All the tests had high specificity levels and negative predictive values. Data from 34 European TVI-PR studies in symptomatic women were pooled. The TVI-PR established in our study was similar to the TVI-PR estimates of 4.8% in Europe and 4.5% in Greece, with the second being higher than those of 2.1% in Northwestern Europe and 1.5% in Southern Europe but closer to that of 6.7% in Türkiye. In Greece, a European country with a relatively high TVI-PR among symptomatic women, the highly sensitive and specific, automated, point-of-care NAAT would facilitate rapid, accurate TVI diagnosis and the treatment of this target population to meet the WHO’s goal of ending STI epidemics by 2030.
Zitieren
APA
Tsoukalas, L., Vassalos, C. M., Gkitsakis, N., Gkotzamani, P., Gkoumalatsou, E., Bakalianou, K., Palla, E., Baka, S., Skanavis, C., & Vassalou, E. (2025). Trichomonas vaginalis in Vaginal Samples from Symptomatic Women in Greece: Assessment of Test Performance and Prevalence Rate, and Comparison with European Prevalence Estimates. Acta Microbiologica Hellenica, 70(3), 29. https://doi.org/10.3390/amh70030029
Vancouver
Tsoukalas L, Vassalos CM, Gkitsakis N, Gkotzamani P, Gkoumalatsou E, Bakalianou K, et al. Trichomonas vaginalis in Vaginal Samples from Symptomatic Women in Greece: Assessment of Test Performance and Prevalence Rate, and Comparison with European Prevalence Estimates. Acta Microbiologica Hellenica. 2025;70(3):29. doi:10.3390/amh70030029
BibTeX
@article{Tsoukalas2025,
author = {Tsoukalas, Lazaros and Vassalos, Constantine M. and Gkitsakis, Nikos and Gkotzamani, Panagiota and Gkoumalatsou, Eleni and Bakalianou, Konstantia and Palla, Eleftheria and Baka, Stavroula and Skanavis, Constantina and Vassalou, Evdokia},
title = {Trichomonas vaginalis in Vaginal Samples from Symptomatic Women in Greece: Assessment of Test Performance and Prevalence Rate, and Comparison with European Prevalence Estimates},
journal = {Acta Microbiologica Hellenica},
year = {2025},
volume = {70},
number = {3},
pages = {29},
doi = {10.3390/amh70030029}
}
EUVIMED